Skip to Main Content

Paper Details

Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Circulation
57
2020
Glucose, Human, Type 2 Diabetes Mellitus, glucose, glycated hemoglobin, heart failure, myocardial infarction, patients, type 2 diabetes mellitus
Author NameAffiliation
Robert M CaliffVerily Life Sciences and Duke University School of Medicine
Robert M CaliffVerily Life Sciences and Duke University School of Medicine
David L DeMetsUniversity of Wisconsin
David L DeMetsUniversity of Wisconsin
Matthew T RoeDuke Clinical Research Institute, Duke University School of Medicine
Yves Rosenbergand Blood Institute
Robert TempleCenter for Drug Evaluation and Research
  • 1 - 7

Datasets

Release 1.2